A phase II, single-arm trial of epratuzumab, an anti-CD22 humanized antibody, in patients with Waldenstrom's macroglobulinaemia

Trial Profile

A phase II, single-arm trial of epratuzumab, an anti-CD22 humanized antibody, in patients with Waldenstrom's macroglobulinaemia

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Epratuzumab (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Sponsors Immunomedics
  • Most Recent Events

    • 05 Feb 2008 Status changed from in progress to dicontinued. Trial terminated due to low accrual.
    • 02 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top